ClinicalTrials.gg
CompletedNCT03203564Updated Sep 25, 2020Results posted

Study Evaluating ECG Effects, Safety, Tolerability and Pharmacokinetics of Single Doses of Modufolin (Arfolitixorin) in Healthy Volunteers Tetrahydrofolate in Healthy Male Volunteers

A Phase 1 interventional study of Modufolin (arfolitixorin) in Phase I Study in Healthy Volunteers to Evaluate ECG Effect, sponsored by Isofol Medical AB. Completed at 1 site in Sweden. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-25.

Sponsored by Isofol Medical AB · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluating ECG effects, safety, tolerability and pharmacokinetics of single ascending dose of Modufolin® in healthy male volunteers

Read the detailed description

An adaptive randomised, double-blind, single-centre, placebo-controlled Phase I study evaluating ECG effects, safety, tolerability and PK of single ascending doses of Modufolin® for Injection, 100 mg in healthy male volunteers. Thirty-three (33) eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort. Within each cohort, subjects will be randomised to receive either placebo (3 subjects) or Modufolin® for Injection, 100 mg (8 subjects). There will be 3 pre-defined ascending dose-levels. Additional dose levels may be considered if recommended by the internal Safety Review cCommittee. There will be an interval between each dose level to allow time for safety data to be analyzed and evaluated by the iSRC. The iSRC will have the choice to decide to escalate the dose as planned, reduce or increase the dose escalation step, repeat the dose, reduce the dose or terminate the study. The total study duration for the subjects will be approximately 5 weeks and there will be in total 3 visits to the clinic. Subjects will be screened for eligibility according to study-specific inclusion/exclusion criteria within 4 weeks prior to start of stud treatment (Visit 1; Screening visit). The subjects will be confined to the research clinic from the evening before dosing (Day -1) until 24 hrs post dose (Days 1 and 2). The subjects should be fasting overnight (8 hrs) before IMP/placebo administration until 4 hrs post-dose. A Follow-up Visit will be performed 5 to 10 days after dose administration of for each cohort.

02

Conditions studied

  • Phase I Study in Healthy Volunteers to Evaluate ECG Effect
03

In context

Lead sponsor

Isofol Medical AB is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide a written for participation in the study.
  2. Healthy male subject aged 18-60 years inclusive.
  3. (BMI) ≥ 18 and ≤ 30 kg/m2 and weight at least 50 kg and no more than 100 kg at screening and body surface area ≤ 2 m2
  4. Clinically normal medical history, physical findings, vital signs, and laboratory values at the time of screening, as judged by the Investigator.
  5. Willing to use condom and highly effective methods with a failure rate of \< 1% to prevent pregnancy1 and drug exposure to a partner and refrain from donating sperm from the date of dosing until 3 months after dosing of the IMP/placebo.

Exclusion criteria

Exclusion Criteria:

    1. History of any disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or subject´s ability to participate in the study.

      1. Any clinically significant illness, medical/surgical procedure or trauma within four weeks of the first administration of IMP/placebo. 3. Any planned major surgery within the duration of the study. 4. Any positive result on screening for serum surface antigen, antibody and (HIV). 5. After 10 minutes (min) supine rest at the time of screening, any vital signs values outside the following ranges:
      • Systolic BP > 150 mm Hg
      • Diastolic BP > 90 mm Hg
      • Pulse \< 40 or > 85 beats per min 6. Prolonged (>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting at the time of screening, as judged by the Investigator.

        1. History of severe allergy/ or on-going allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to Modufolin® (i.e., folate derivatives). 8. Regular use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, vitamins and minerals within two weeks prior to the administration of IMP/placebo, except occasional intake of paracetamol (maximum 2000 mg/day; and not exceeding 3 000 mg/week), at the discretion of the Investigator and nasal decongestants without cortisone or antihistamine for a maximum of 10 days, at the discretion of the Investigator. 9. Regular use of any prescribed or non-prescribed medication which could influence folate and vitamin B12 status within 30 days prior to the administration of IMP/placebo.
        1. Administration of another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment with less than three months between administration of last dose and first dose of IMP/placebo in this study. Subjects consented and screened but not dosed in previous phase I studies are not excluded. 11. Current smokers or users of nicotine products. Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than three times per week is allowed before screening visit. 12. Positive screen for drugs of abuse or alcohol at screening or on admission to the unit prior to administration of the IMP/placebo. 13. Current or history of alcohol abuse and/or use of anabolic steroids or drugs of abuse.
        1. Intake of xanthine and/or taurine containing energy drinks within two days prior to screening.
        1. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to dosing. 16. Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Active comparator
    Modufolin® for injection, 200, 350 and 500 mg/m2

    Three cohorts, 8 subjects will be randomised to Modufolin ® for injection 100 mg

    Drug: Modufolin (arfolitixorin)

  • Placebo comparator
    0.9% NaCl sterile solution

    Three cohorts, 3 subjects will be randomised to placebo

    Drug: Modufolin (arfolitixorin)

Interventions

  • Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)

    Also known as: arfolitixorin

06

What researchers measure

Primary outcomes

  1. Change-from-baseline QTcF (ΔQTcF)

    At each nominal time point specified in the CSP, up to 10 ECG replicates were extracted with TQT Plus methods. TQT Plus ECG extraction technique: Twelve-lead ECGs were extracted from continuous recordings (Holter recordings) prior to and serially after IMP administration at time points as shown in the Schedule of events. Subjects were supinely resting for at least 10 min prior to time points for ECG recordings. The 12-lead Holter and ECG equipment were supplied and supported by iCardiac Technologies, Inc. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min pre-dose) on Day 1.

    Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.

Secondary outcomes

  1. Relationship Between ΔΔQTc and Modufolin® (and Metabolites) Plasma Concentrations

    Predicted ΔΔQTcF interval at geometric mean Cmax for 5,10-MTHF, THF, and 5-Formyl-THF and geometric mean concentration of 5-Methyl-THF observed at 5 minutes post-dose The relationship between plasma concentrations of 5,10-MTHF, THF, 5-Methyl-THF, and 5-Formyl-THF, and change-from-baseline QTcF (ΔQTcF) was quantified using a linear mixed-effects modeling approach with separate analyses for each of the analytes (5,10-MTHF, THF 5-Methyl-THF, and 5-Formyl-THF) initially, with ΔQTcF as the dependent variable, plasma concentration of 5,10-MTHF (or THF, 5-Methyl-THF, or 5-Formyl-THF) as a continuous covariate (i.e., 0 for placebo), centered baseline QTcF as an additional covariate, treatment (active = 1 or placebo = 0) and time (i.e., time point) as categorical factors, and a random intercept and slope per subject. The degrees of freedom estimates were determined by the Kenward-Roger method.

    Time frame: 5 minute post-dose time point

  2. Change-from-baseline Heart Rate (ΔHR)

    The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.

    Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.

  3. Change-from-baseline PR (ΔPR)

    The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.

    Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.

  4. Change-from-baseline QRS (ΔQRS)

    The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.

    Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.

  5. Number of Participants With Categorical QTcF Outliers

    QTcF outliers per absolute category across treatment groups and QTcF outliers per change-from-baseline category (ΔQTcF)

    Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.

  6. Categorical Outliers for HR, PR Interval, QRS Interval

    Categorical Analysis of outliers for HR, PR, and QRS intervals

    Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.

  7. Categorical Analysis for T Wave Morphology

    Categorical T-wave morphology analysis and measurement of PR and QRS intervals were fully performed manually in three of the 10 ECG replicates at each time point. Final quality control and diagnostic interpretations were performed by the study cardiologist. When the results for each time point were compiled in the final data set, the comparison was made between ECG parameters from the three manually reviewed ECGs versus the 10 ECG replicates for quality control purposes. No treatment emergent T wave morphology changes were observed. In addition to the T-wave categorical analysis, the presence of abnormal U-waves was noted.

    Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.

  8. Physical Examination

    A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. Physical examination findings were categorized as Normal, Abnormal non-clinical significant (NCS), and Abnormal clinical significant (CS).

    Time frame: At visit 1 (screening) and follow-up

  9. Systolic Blood Pressure

    Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest.

    Time frame: Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).

  10. Diastolic Blood Pressure

    Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest. There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.

    Time frame: Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).

  11. Vital Signs: Pulse

    Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest. There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.

    Time frame: Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).

  12. Safety Laboratory Measurements

    The following safety laboratory parameters were assessed: Clinical Chemistry: Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Albumin, Aspartate aminotransferase (AST), Bilirubin (total and conjugated), Calcium, Chloride, Creatinine, Magnesium, Phosphorous, Potassium, Sodium, Urea nitrogen, Uric acid. Haematology: Haematocrit, Haemoglobin (Hb), Platelet count, Red blood cell (RBC) count, White blood cell (WBC) count with differential count. Urinalysis (dip stick):Glucose, Erythrocytes, Nitrite, Protein, Specific gravity, pH.

    Time frame: Pre-dose at screening (visit 1) and -2h (visit 2). Post-dose at following timepoints: 24 h (visit 2) and at follow-up (visit 3)

  13. Frequency, Seriousness and Intensity of AEs

    An overall summary of AEs occurring after first administration of IMP (TEAE) is presented by treatment

    Time frame: From start of IMP administration to follow-up visit

  14. Plasma PK Characteristics: C0

    The mean back-extrapolated concentration at time 0 h (C0) was calculated for MTHF

    Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h. pre-dose to 24 h post-dose

  15. Plasma PK Characteristics: C5min

    Measured concentration at 5 min post dose (C5min) of MTHF and 5-Formyl-THF

    Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h

  16. Plasma PK Characteristics: AUClast

    Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted

    Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.

  17. Plasma PK Characteristics: AUClast/Dose

    Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.

    Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.

  18. Plasma PK Characteristics: Timepoint for Last Measured Plasma Concentration (Tlast)

    Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.

    Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.

  19. Plasma PK Characteristics: t1/2

    Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted:

    Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.

  20. Plasma PK Characteristics: CL

    Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.

    Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.

  21. Plasma PK Characteristics: Vss

    Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted

    Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h

  22. Plasma PK Characteristics: Cmax

    Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted

    Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.

  23. Plasma PK Characteristics: Tmax

    Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted

    Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.

  24. Plasma PK Characteristics: Cmax/Dose for Metabolite 5-Formyl-THF

    Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted. Only the metabolite 5-Formyl-THF has values above LLOQ and are presented below.

    Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h

  25. Number of Subjects With AEs

    An overall summary of subjects with AEs occurring after first administration of IMP (TEAE), number of related TEAEs and number of withdrawals due to TEAEs are presented by treatment

    Time frame: From start of IMP administration to follow-up visit

07

Results

Posted Mar 19, 2020

Participant flow

Subjects were recruited from a database of healthy volunteers at CTC and from advertising in media, including social media.

Participant flow — Overall Study
Milestone200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
Started8889
Completed8889
Not completed0000

Outcome measures

PrimaryChange-from-baseline QTcF (ΔQTcF)

At each nominal time point specified in the CSP, up to 10 ECG replicates were extracted with TQT Plus methods. TQT Plus ECG extraction technique: Twelve-lead ECGs were extracted from continuous recordings (Holter recordings) prior to and serially after IMP administration at time points as shown in the Schedule of events. Subjects were supinely resting for at least 10 min prior to time points for ECG recordings. The 12-lead Holter and ECG equipment were supplied and supported by iCardiac Technologies, Inc. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min pre-dose) on Day 1.

Time frame:
Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Reported as:
Least squares mean · msec
Change-from-baseline QTcF (ΔQTcF)
msec200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
End of infusion2.8 ± 2.859.2 ± 2.848.5 ± 2.871.1 ± 2.69
5 min post-dose11.2 ± 2.289.1 ± 2.2822.4 ± 2.310.0 ± 2.16
15 min post-dose3.1 ± 1.487.5 ± 1.4712.4 ± 1.510.2 ± 1.40
30 min post-dose1.2 ± 1.432.5 ± 1.424.2 ± 1.470.8 ± 1.36
1 h post-dose-1.2 ± 1.38-0.7 ± 1.38-0.9 ± 1.421.4 ± 1.32
2 h post-dose-3.5 ± 1.97-1.7 ± 1.961.0 ± 1.990.7 ± 1.86
3 h post-dose-2.8 ± 2.58-0.8 ± 2.580.9 ± 2.603.8 ± 2.44
4 h post-dose-3.3 ± 2.700.7 ± 2.700.0 ± 2.722.6 ± 2.55
5 h post-dose5.4 ± 3.252.6 ± 3.370.8 ± 3.2711.5 ± 3.07
6 h post-dose-0.8 ± 2.73-2.5 ± 2.72-6.7 ± 2.756.4 ± 2.58
8 h post-dose-5.5 ± 2.91-5.5 ± 2.90-7.7 ± 2.93-0.9 ± 2.75
12 h post-dose-4.5 ± 2.86-6.6 ± 2.86-4.1 ± 2.952.8 ± 2.70
24 h post-dose-5.9 ± 2.85-8.1 ± 2.84-4.6 ± 3.01-1.3 ± 2.69
Statistical analysis
  • 200 mg/m2 of Modufolin® vs 350 mg/m2 of Modufolin® vs 500 mg/m2 of Modufolin® vs Placebo · Mean difference (final values): 7.4 · 90% CI 0.68 to 14.12Parameter estimate is done for Placebo-corrected change-from baseline QTcF (ΔΔQTcF) for Modufolin 500 mg/m2 at end of infusion.
SecondaryRelationship Between ΔΔQTc and Modufolin® (and Metabolites) Plasma Concentrations

Predicted ΔΔQTcF interval at geometric mean Cmax for 5,10-MTHF, THF, and 5-Formyl-THF and geometric mean concentration of 5-Methyl-THF observed at 5 minutes post-dose The relationship between plasma concentrations of 5,10-MTHF, THF, 5-Methyl-THF, and 5-Formyl-THF, and change-from-baseline QTcF (ΔQTcF) was quantified using a linear mixed-effects modeling approach with separate analyses for each of the analytes (5,10-MTHF, THF 5-Methyl-THF, and 5-Formyl-THF) initially, with ΔQTcF as the dependent variable, plasma concentration of 5,10-MTHF (or THF, 5-Methyl-THF, or 5-Formyl-THF) as a continuous covariate (i.e., 0 for placebo), centered baseline QTcF as an additional covariate, treatment (active = 1 or placebo = 0) and time (i.e., time point) as categorical factors, and a random intercept and slope per subject. The degrees of freedom estimates were determined by the Kenward-Roger method.

Time frame:
5 minute post-dose time point
Reported as:
Geometric mean · msec / ng/mL
Relationship Between ΔΔQTc and Modufolin® (and Metabolites) Plasma Concentrations
msec / ng/mL200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®
5,10-MTHF24111.78 (19194.04 to 30289.52)51566.94 (46351.78 to 57368.87)69012.28 (60609.82 to 78579.59)
THF15995.29 (13750.28 to 18606.83)29386.77 (26812.58 to 32208.09)44018.37 (40400.31 to 47960.44)
5-Methyl-THF218.18 (176.04 to 270.40)544.01 (435.70 to 679.25)333.09 (279.56 to 396.86)
5-Formyl-THF296.43 (114.76 to 765.71)567.17 (414.42 to 776.22)379.33 (333.23 to 431.81)
ΔΔQTcF4.15 (0.97 to 7.33)13.25 (9.36 to 17.14)19.88 (15.40 to 24.35)
SecondaryChange-from-baseline Heart Rate (ΔHR)

The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.

Time frame:
Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Reported as:
Least squares mean · bpm
Change-from-baseline Heart Rate (ΔHR)
bpm200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
End of infusion2.6 ± 1.912.7 ± 1.912.0 ± 1.92-2.1 ± 1.80
5 min post-dose8.2 ± 2.567.4 ± 2.5513.3 ± 2.560.0 ± 2.41
15 min post-dose3.9 ± 1.633.6 ± 1.632.6 ± 1.64-1.6 ± 1.53
30 min post-dose3.3 ± 2.001.3 ± 2.003.0 ± 2.00-0.7 ± 1.88
1 h post-dose5.0 ± 1.900.0 ± 1.90-0.9 ± 1.91-1.3 ± 1.79
2 h post-dose3.2 ± 1.52-0.1 ± 1.52-2.6 ± 1.53-1.8 ± 1.43
3 h post-dose2.2 ± 1.470.3 ± 1.460.3 ± 1.47-2.3 ± 1.38
4 h post-dose1.7 ± 1.822.0 ± 1.820.2 ± 1.83-3.3 ± 1.72
5 h post-dose11.9 ± 2.0612.4 ± 2.128.9 ± 2.069.5 ± 1.94
6 h post-dose8.3 ± 2.5212.5 ± 2.526.2 ± 2.535.4 ± 2.38
8 h post-dose8.1 ± 2.248.0 ± 2.232.5 ± 2.242.1 ± 2.11
12 h post-dose7.6 ± 2.415.3 ± 2.413.6 ± 2.540.6 ± 2.27
24 h post-dose6.0 ± 2.805.7 ± 2.808.0 ± 3.008.6 ± 2.64
SecondaryChange-from-baseline PR (ΔPR)

The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.

Time frame:
Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Reported as:
Least squares mean · msec
Change-from-baseline PR (ΔPR)
msec200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
End of infusion-1.6 ± 2.08-4.4 ± 2.08-2.1 ± 2.08-1.6 ± 1.96
5 min post-dose-1.5 ± 2.07-4.5 ± 2.07-3.1 ± 2.07-0.1 ± 1.96
15 min post-dose-2.3 ± 2.61-1.2 ± 2.610.2 ± 2.613.8 ± 2.46
30 min post-dose-1.7 ± 2.11-3.7 ± 2.111.3 ± 2.112.9 ± 1.99
1 h post-dose-5.2 ± 1.89-3.6 ± 1.89-0.3 ± 1.890.4 ± 1.79
2 h post-dose-4.1 ± 2.13-4.1 ± 2.131.1 ± 2.133.1 ± 2.01
3 h post-dose-5.3 ± 2.14-4.2 ± 2.14-1.6 ± 2.141.2 ± 2.02
4 h post-dose-5.2 ± 1.84-4.6 ± 1.84-2.1 ± 1.841.4 ± 1.74
5 h post-dose-8.8 ± 2.59-7.1 ± 2.71-7.8 ± 2.59-3.5 ± 2.44
6 h post-dose-9.4 ± 2.04-8.4 ± 2.04-5.8 ± 2.04-3.9 ± 1.93
8 h post-dose-8.6 ± 2.62-7.2 ± 2.62-4.3 ± 2.62-5.6 ± 2.47
12 h post-dose-7.9 ± 3.12-1.5 ± 3.12-6.9 ± 3.22-1.7 ± 2.94
24 h post-dose-5.9 ± 2.77-5.6 ± 2.77-6.4 ± 2.88-6.8 ± 2.61
SecondaryChange-from-baseline QRS (ΔQRS)

The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.

Time frame:
Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Reported as:
Least squares mean · msec
Change-from-baseline QRS (ΔQRS)
msec200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
End of infusion-0.1 ± 0.27-0.2 ± 0.27-0.1 ± 0.270.5 ± 0.25
5 min post-dose-0.7 ± 0.28-0.8 ± 0.28-1.2 ± 0.280.0 ± 0.26
15 min post-dose-0.2 ± 0.25-0.3 ± 0.25-0.1 ± 0.250.0 ± 0.24
30 min post-dose-0.7 ± 0.270.0 ± 0.27-0.5 ± 0.270.0 ± 0.26
1 h post-dose-0.2 ± 0.260.1 ± 0.260.2 ± 0.260.0 ± 0.24
2 h post-dose-0.2 ± 0.220.0 ± 0.22-0.1 ± 0.22-0.1 ± 0.21
3 h post-dose0.0 ± 0.30-0.1 ± 0.31-0.4 ± 0.300.2 ± 0.29
4 h post-dose0.1 ± 0.39-0.5 ± 0.390.2 ± 0.380.9 ± 0.36
5 h post-dose0.4 ± 0.470.4 ± 0.490.1 ± 0.470.2 ± 0.45
6 h post-dose-0.3 ± 0.52-0.4 ± 0.52-0.8 ± 0.52-0.7 ± 0.49
8 h post-dose-0.3 ± 0.53-0.3 ± 0.53-0.5 ± 0.53-0.6 ± 0.50
12 h post-dose0.5 ± 0.560.3 ± 0.56-0.6 ± 0.58-1.0 ± 0.53
24 h post-dose0.0 ± 0.450.4 ± 0.45-0.9 ± 0.47-0.9 ± 0.42
SecondaryNumber of Participants With Categorical QTcF Outliers

QTcF outliers per absolute category across treatment groups and QTcF outliers per change-from-baseline category (ΔQTcF)

Time frame:
Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Reported as:
Count of participants · Participants
Number of Participants With Categorical QTcF Outliers
Participants200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
No. participants with QTcF > 450 and ≤ 480 msec0010
No. participants with QTcF > 480 and ≤ 500 msec0000
No. participants with QTcF > 500 msec0000
No. participants with ΔQTcF of > 30 and ≤ 60 msec0020
No. participants with ΔQTcF > 60 msec0000
SecondaryCategorical Outliers for HR, PR Interval, QRS Interval

Categorical Analysis of outliers for HR, PR, and QRS intervals

Time frame:
Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Reported as:
Count of participants · Participants
Categorical Outliers for HR, PR Interval, QRS Interval
Participants200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
HR changes >25% decrease from baseline to <50 bpm0000
HR changes >25% increase from baseline to >100bpm0000
PR changes > 25% increase from baseline to >200ms0000
QRS changes > 25% increase from baseline to >120ms0000
SecondaryCategorical Analysis for T Wave Morphology

Categorical T-wave morphology analysis and measurement of PR and QRS intervals were fully performed manually in three of the 10 ECG replicates at each time point. Final quality control and diagnostic interpretations were performed by the study cardiologist. When the results for each time point were compiled in the final data set, the comparison was made between ECG parameters from the three manually reviewed ECGs versus the 10 ECG replicates for quality control purposes. No treatment emergent T wave morphology changes were observed. In addition to the T-wave categorical analysis, the presence of abnormal U-waves was noted.

Time frame:
Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Reported as:
Count of participants · Participants
Categorical Analysis for T Wave Morphology
Participants200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
Flat0000
Notched (+)0000
Biphasic0000
Normal (-)0000
Notched (-)0000
U wave presence0000
SecondaryPhysical Examination

A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. Physical examination findings were categorized as Normal, Abnormal non-clinical significant (NCS), and Abnormal clinical significant (CS).

Time frame:
At visit 1 (screening) and follow-up
Reported as:
Count of participants · Participants
Physical Examination
Participants200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
Abnormal NCS - Visit 10010
Abnormal CS - Visit 10000
Abnormal NCS - Follow-up0000
Abnormal CS - Follow-up0000
SecondarySystolic Blood Pressure

Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest.

Time frame:
Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).
Reported as:
Mean · mmHg
Systolic Blood Pressure
mmHg200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
Screening115.50 ± 7.60121.25 ± 7.07116.63 ± 9.56125.56 ± 14.82
Visit 2 Day 1 (-00:15)111.38 ± 10.94109.38 ± 9.36117.38 ± 8.11123.67 ± 24.63
Visit 2 Day 1 (03:00)108.88 ± 7.12105.00 ± 6.89112.50 ± 9.29111.22 ± 7.87
Visit 2 Day 1 (05:00)115.50 ± 5.61115.00 ± 8.50120.88 ± 7.94113.00 ± 13.32
Visit 2 Day 1 (08:00)118.50 ± 9.06113.88 ± 6.75115.63 ± 5.83114.89 ± 10.61
Visit 2 Day 2117.75 ± 9.29114.13 ± 5.77120.88 ± 8.46119.00 ± 10.02
Follow-up121.38 ± 8.93115.63 ± 11.03119.38 ± 10.21122.11 ± 12.24
SecondaryDiastolic Blood Pressure

Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest. There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.

Time frame:
Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).
Reported as:
Mean · mmHg
Diastolic Blood Pressure
mmHg200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
Screening68.63 ± 5.2169.75 ± 8.5172.25 ± 8.0173.56 ± 11.75
Visit 2 Day 1 (-00:15)69.63 ± 3.7465.88 ± 6.4275.38 ± 2.7769.56 ± 9.06
Visit 2 Day 1 (03:00)69.00 ± 6.8964.38 ± 7.3772.63 ± 5.7165.56 ± 11.20
Visit 2 Day 1 (05:00)65.63 ± 5.8862.38 ± 5.0472.25 ± 7.1567.00 ± 11.16
Visit 2 Day 1 (08:00)69.00 ± 7.2964.50 ± 3.8970.25 ± 6.3666.22 ± 9.59
Visit 2 Day 271.50 ± 10.2369.38 ± 4.5074.25 ± 5.4771.11 ± 8.15
Follow-up68.25 ± 4.5370.25 ± 7.8171.00 ± 8.0770.11 ± 7.99
SecondaryVital Signs: Pulse

Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest. There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.

Time frame:
Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).
Reported as:
Mean · bpm
Vital Signs: Pulse
bpm200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
Screening59.50 ± 5.2166.50 ± 9.3862.00 ± 11.2463.22 ± 12.88
Visit 2 Day 1 (-00:15)55.25 ± 5.4452.00 ± 8.6056.38 ± 5.5854.44 ± 11.34
Visit 2 Day 1 03:00)56.25 ± 5.5053.13 ± 11.0153.75 ± 4.9550.33 ± 6.60
Visit 2 Day 1 (05:00)65.38 ± 4.0065.25 ± 9.6666.00 ± 11.6061.44 ± 8.92
Visit 2 Day 1 (08:00)60.25 ± 6.8259.00 ± 5.8356.75 ± 7.2155.67 ± 7.23
Visit 2 Day 259.38 ± 9.5357.63 ± 8.9161.75 ± 13.4861.22 ± 11.31
Follow-up66.25 ± 9.0467.88 ± 12.9169.25 ± 16.2667.44 ± 14.47
SecondarySafety Laboratory Measurements

The following safety laboratory parameters were assessed: Clinical Chemistry: Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Albumin, Aspartate aminotransferase (AST), Bilirubin (total and conjugated), Calcium, Chloride, Creatinine, Magnesium, Phosphorous, Potassium, Sodium, Urea nitrogen, Uric acid. Haematology: Haematocrit, Haemoglobin (Hb), Platelet count, Red blood cell (RBC) count, White blood cell (WBC) count with differential count. Urinalysis (dip stick):Glucose, Erythrocytes, Nitrite, Protein, Specific gravity, pH.

Time frame:
Pre-dose at screening (visit 1) and -2h (visit 2). Post-dose at following timepoints: 24 h (visit 2) and at follow-up (visit 3)
Reported as:
Number · Clinically relevant changes
Safety Laboratory Measurements
Clinically relevant changes200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
Safety Laboratory Measurements0000
SecondaryFrequency, Seriousness and Intensity of AEs

An overall summary of AEs occurring after first administration of IMP (TEAE) is presented by treatment

Time frame:
From start of IMP administration to follow-up visit
Reported as:
Number · Adverse events
Frequency, Seriousness and Intensity of AEs
Adverse events200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
No. of TEAEs88162
No. of subject-unique TEAEs87162
Subject-unique related TEAEs74140
SAEs0000
SecondaryPlasma PK Characteristics: C0

The mean back-extrapolated concentration at time 0 h (C0) was calculated for MTHF

Time frame:
Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h. pre-dose to 24 h post-dose
Reported as:
Mean · ng/mL
Plasma PK Characteristics: C0
ng/mL200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
Plasma PK Characteristics: C034200 ± 1030078300 ± 1260099000 ± 23100—
SecondaryPlasma PK Characteristics: C5min

Measured concentration at 5 min post dose (C5min) of MTHF and 5-Formyl-THF

Time frame:
Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h
Reported as:
Mean · ng/mL
Plasma PK Characteristics: C5min
ng/mL200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
MTHF24600 ± 648052200 ± 853070100 ± 13100—
5-Formyl-THF443 ± 432609 ± 240374 ± 83.2—
SecondaryPlasma PK Characteristics: AUClast

Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted

Time frame:
Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Reported as:
Mean · h*ng/mL
Plasma PK Characteristics: AUClast
h*ng/mL200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
MTHF10900 ± 168019700 ± 199031100 ± 3210—
THF31800 ± 378053100 ± 1000090100 ± 17500—
5-Methyl-THF23400 ± 447038500 ± 638047400 ± 7540—
SecondaryPlasma PK Characteristics: AUClast/Dose

Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.

Time frame:
Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Reported as:
Mean · (h*ng/mL)/mg
Plasma PK Characteristics: AUClast/Dose
(h*ng/mL)/mg200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
MTHF29.2 ± 5.2729.8 ± 2.7432.9 ± 4.93—
THF85.0 ± 11.880.1 ± 14.095.0 ± 19.2—
5-Methyl-THF62.7 ± 12.558.3 ± 9.8749.9 ± 7.91—
5-Formyl-THF2.33 ± 1.971.24 ± 1.220.343 ± 0.580—
SecondaryPlasma PK Characteristics: Timepoint for Last Measured Plasma Concentration (Tlast)

Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.

Time frame:
Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Reported as:
Mean · hour
Plasma PK Characteristics: Timepoint for Last Measured Plasma Concentration (Tlast)
hour200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
MTHF4.38 ± 1.955.37 ± 1.306.75 ± 2.31—
THF7.01 ± 1.528.01 ± 0.01788.75 ± 2.12—
5-Methyl-THF24.0 ± 0.033924.0 ± 0.098023.8 ± 0.135—
5-Formyl-THF3.41 ± 2.943.00 ± 2.921.40 ± 2.67—
SecondaryPlasma PK Characteristics: t1/2

Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted:

Time frame:
Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Reported as:
Mean · hour
Plasma PK Characteristics: t1/2
hour200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
MTHF0.989 ± 0.9361.87 ± 0.6342.03 ± 0.780—
THF1.35 ± 0.2111.51 ± 0.2671.59 ± 0.370—
5-Methyl-THF5.54 ± 0.7145.66 ± 0.6445.84 ± 0.634—
SecondaryPlasma PK Characteristics: CL

Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.

Time frame:
Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Reported as:
Mean · L/h
Plasma PK Characteristics: CL
L/h200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
MTHF38.6 ± 1.8435.5 ± 3.0530.6 ± 5.14—
THF11.6 ± 1.4712.6 ± 2.5810.7 ± 2.37—
5-Methyl-THF15.6 ± 3.1116.5 ± 2.6319.1 ± 3.49—
SecondaryPlasma PK Characteristics: Vss

Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted

Time frame:
Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h
Reported as:
Mean · litre
Plasma PK Characteristics: Vss
litre200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
MTHF18.1 ± 9.3820.4 ± 6.1018.5 ± 6.07—
THF21.8 ± 3.3024.9 ± 4.1721.6 ± 4.43—
5-Methyl-THF138 ± 28.4153 ± 27.4181 ± 27.9—
SecondaryPlasma PK Characteristics: Cmax

Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted

Time frame:
Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Reported as:
Mean · ng/mL
Plasma PK Characteristics: Cmax
ng/mL200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
THF16400 ± 361029600 ± 397044400 ± 6090—
5-Methyl-THF2490 ± 4503950 ± 7554740 ± 484—
5-Formyl-THF642 ± 474619 ± 257386 ± 75.3—
SecondaryPlasma PK Characteristics: Tmax

Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted

Time frame:
Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Reported as:
Mean · hour
Plasma PK Characteristics: Tmax
hour200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
THF0.267 ± 0.3340.123 ± 0.07860.300 ± 0.179—
5-Methyl-THF3.12 ± 0.8353.50 ± 1.073.63 ± 0.519—
5-Formyl-THF0.0778 ± 0.02550.102 ± 0.06010.142 ± 0.145—
SecondaryPlasma PK Characteristics: Cmax/Dose for Metabolite 5-Formyl-THF

Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted. Only the metabolite 5-Formyl-THF has values above LLOQ and are presented below.

Time frame:
Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h
Reported as:
Mean · ng/mL/mg
Plasma PK Characteristics: Cmax/Dose for Metabolite 5-Formyl-THF
ng/mL/mg200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
Plasma PK Characteristics: Cmax/Dose for Metabolite 5-Formyl-THF1.73 ± 1.330.934 ± 0.3790.407 ± 0.0826—
SecondaryNumber of Subjects With AEs

An overall summary of subjects with AEs occurring after first administration of IMP (TEAE), number of related TEAEs and number of withdrawals due to TEAEs are presented by treatment

Time frame:
From start of IMP administration to follow-up visit
Reported as:
Number · Subjects
Number of Subjects With AEs
Subjects200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
Subjects with at least one TEAE6581
Subjects with at least one related TEAE5380
Withdrawals due to TEAE0000

Adverse events

Collected over Adverse event data was collected from start of IMP administration to last subject last visit, thus during a period of little less than 2 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 mg/m2 of Modufolin®0/8 (0%)0/8 (0%)6/8 (75%)
350 mg/m2 of Modufolin®0/8 (0%)0/8 (0%)5/8 (62.5%)
500 mg/m2 of Modufolin®0/8 (0%)0/8 (0%)8/8 (100%)
Placebo0/9 (0%)0/9 (0%)1/9 (11.1%)
Most frequent other events
Showing 10 of 16
Most frequent other events
Event200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®Placebo
NauseaGastrointestinal disorders1/82/84/80/9
Nasal congestionRespiratory, thoracic and mediastinal disorders0/81/83/80/9
DysgeusiaNervous system disorders0/80/82/80/9
ParaesthesiaNervous system disorders1/80/82/80/9
Paraesthesia oralNervous system disorders2/81/80/80/9
SneezingRespiratory, thoracic and mediastinal disorders0/80/81/80/9
HeadacheNervous system disorders1/81/81/81/9
HypoaesthesiaNervous system disorders0/81/80/80/9
Hypoaesthesia oralNervous system disorders0/80/81/80/9
ChillsGeneral disorders1/80/80/80/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®PlaceboTotal
<=18 years00000
Between 18 and 65 years888933
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®PlaceboTotal
Female00000
Male888933
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®PlaceboTotal
Hispanic or Latino10102
Not Hispanic or Latino787931
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)200 mg/m2 of Modufolin®350 mg/m2 of Modufolin®500 mg/m2 of Modufolin®PlaceboTotal
Sweden888933
08

Study locations

1 site
  • CTC Clinical Trial Consultants
    Uppsala, 75185, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Aug 2017, 1 month.

Results were first posted in Mar 2020, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2017
First posted
Jun 29, 2017
StartActual
Jul 4, 2017
Primary completionActual
Aug 25, 2017
CompletionActual
Aug 25, 2017
Results first posted
Mar 19, 2020
Last update
Sep 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03203564
Lead sponsor
Isofol Medical AB
Responsible party
Sponsor
First posted
Jun 29, 2017
Start date
Jul 4, 2017
Primary completion
Aug 25, 2017
Completion
Aug 25, 2017
Results posted
Mar 19, 2020
Last update
Sep 25, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: L-(+)-methylenetetrahydrofolic acid

Start the discussion